Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Chemoradiation With or Without Panitumumab in High-Risk HNSCC
NCT01142414Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of panitumumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease-Free Survival. Status: withdrawn.
02
Drugs
panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01142414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142414.